Document Detail

Therapeutic potential of RNA interference against cellular targets of HIV infection.
MedLine Citation:
PMID:  17952669     Owner:  NLM     Status:  MEDLINE    
RNA interference is not only very promising in identifying new targets for drug development, siRNA/shRNA themselves may be directly used as therapeutic agents. In inhibiting viral infections by RNA interference, both viral targets and cellular proteins have been evaluated. Most of the early studies in this field had chosen viral targets for RNA interference. However, recent efforts are mainly focusing on cellular proteins for RNA silencing due to the realization that a variety of viral responses substantially minimize siRNA effects. With the application of siRNA approaching, many new cellular targets relevant to HIV infection have been identified. The value of siRNA/shRNA in the treatment of AIDS is largely dependent on better understanding of the biology of HIV replication. Efforts in the identification of cellular processes with the employment of siRNA/shRNA have shed some new lights on our understanding of how HIV infection occurs. Furthermore, the relative specific effects and simplicity of design makes siRNA/shRNA themselves to be favorable drug leads.
Jia Zhang; Y O Wu; Li Xiao; Kai Li; L L Chen; P Sirois
Related Documents :
15699349 - Hepatitis c virus rna replication is regulated by host geranylgeranylation and fatty ac...
25292029 - Comparison of viral hepatitis-associated hepatocellular carcinoma due to hbv and hcv - ...
15190019 - Non-nucleoside inhibitors of the hcv polymerase.
25294379 - Association between serum vitamin d and severity of liver fibrosis in chronic hepatitis...
25173399 - A chimeric mouse model to study immunopathogenesis of hcv infection.
15113899 - Identification of unique hepatitis c virus quasispecies in the central nervous system a...
20539279 - Ex vivo t cell-based hiv suppression assay to evaluate hiv-specific cd8+ t-cell responses.
16055879 - Tuberculosis, hiv seroprevalence and intravenous drug abuse in prisoners.
25453869 - Sofosbuvir as backbone of interferon free treatments.
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2007-09-15
Journal Detail:
Title:  Molecular biotechnology     Volume:  37     ISSN:  1073-6085     ISO Abbreviation:  Mol. Biotechnol.     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-22     Completed Date:  2008-01-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423533     Medline TA:  Mol Biotechnol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  225-36     Citation Subset:  IM    
Gene Core, The Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acquired Immunodeficiency Syndrome / genetics,  therapy
Gene Targeting / methods*
Gene Therapy / methods
Gene Transfer Techniques
Genes, Viral
HIV Infections / genetics*,  therapy*
Models, Biological
RNA Interference / physiology*
RNA, Small Interfering / adverse effects,  therapeutic use*
Substrate Specificity
Reg. No./Substance:
0/RNA, Small Interfering

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Isolation and purification of RNA from tissues rich in polyphenols, polysaccharides, and pigments of...
Next Document:  Chemical genomics: a challenge for de novo drug design.